Why FDA Said No to a Melanoma Drug

Questions over trial design and political pressure shadowed the rejection of Replimune’s RP1 treatment.

1

The FDA rejected the melanoma drug RP1 despite clinical trial data showing it prolonged lives for a third of participants.
2

Concerns about RP1's trial design, including the lack of a control arm, contributed to the FDA's decision to deny approval.
3

The rejection of RP1 has raised fears about its impact on drug development and investor confidence in the pharmaceutical industry.
4

The FDA's decision reflects a shift in agency culture under recent leadership, leading to speculation about the decision-making process.
5

Replimune, the drug's manufacturer, faces significant challenges, including staff layoffs and financial instability following the FDA ruling.